^
Association details:
| Biomarker: | MYD88 L265P + CD79B mutation |
|---|---|
| Cancer: | Lymphoma |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Excerpt:
We performed a proof-of-concept phase Ib study of ibrutinib monotherapy followed by ibrutinib plus chemotherapy (DA-TEDDi-R). In 18 PCNSL patients, 94% showed tumor reductions with ibrutinib alone, including patients having PCNSL with CD79B and/or MYD88 mutations, and 86% of evaluable patients achieved complete remission with DA-TEDDi-R.
Secondary therapy:
TEDDi-R
DOI:
10.1016/j.ccell.2017.04.012
Source:
Title:
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Excerpt:
We performed a proof-of-concept phase Ib study of ibrutinib monotherapy followed by ibrutinib plus chemotherapy (DA-TEDDi-R). In 18 PCNSL patients, 94% showed tumor reductions with ibrutinib alone, including patients having PCNSL with CD79B and/or MYD88 mutations, and 86% of evaluable patients achieved complete remission with DA-TEDDi-R.
DOI:
10.1016/j.ccell.2017.04.012
